AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Asthma & COPD Therapeutics Market, Bronchodilator Monotherapy Market Outlook, 2025 - ResearchAndMarkets.com

May 9, 2019

DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Global Asthma & COPD Therapeutics Market, Bronchodilator Monotherapy Market Outlook 2025” report has been added to ResearchAndMarkets.com’s offering.

Demand for combination therapies for the treatment of respiratory diseases has been on an increasing spree. COPD medications such as long-acting beta-2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) combination in the inhaler is one of the latest therapeutics being used for the treatment of Asthma and COPD.

The report provides in-depth analysis of the current scenario, detailed market outlook of the global Asthma & COPD therapeutics market overall as well as across various geographies. Geographical analysis is done across major markets such as the US, Japan, China, Germany & France.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market-specific growth opportunities in global Asthma & COPD therapeutics market.

Key Vendors

  • AstraZeneca plc
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Merck & Co. Inc.

Topics Covered

1. Executive Summary

2. Research Methodology

3. Respiratory Diseases

3.1 Background

3.2 Types

3.3 Asthma

4. Market Analysis

4.1 Market Sizing (Actual & Forecasted)

4.2 Market Share Analysis

4.2.1 Market Share by Disease

4.2.2 Market Share by Segments

4.2.3 Market Share by Therapeutic Classes

4.2.4 Market Share by Nations

5. Treatment

5.1 Anti-inflammatory Drugs

5.1.1 Inhaled Corticosteroids (ICS)

5.2 Bronchodilator Monotherapy

5.2.1 Long-Acting Beta Agonists (LABA)

5.2.2 Short-Acting Beta Agonists (SABA)

5.3 Others

5.3.1 Overview

5.3.2 Market Sizing (Actual & Forecasted)

6. Country Analysis

6.1 The US

6.2 Germany

6.3 France

6.4 Japan

6.5 China

7. Market Dynamics

7.1 Industry Trends & Development

7.1.1 Connected Health Solutions

7.1.2 Higher Demand for Combination Therapies

7.1.3 Advent of Stem Cell Therapy

7.2 Growth Drivers

7.2.1 Prevalence of Respiratory Diseases

7.2.2 Environmental Pollution

7.2.3 Government Impetus

7.2.4 Rise in Number of Smokers

7.2.5 Growing Geriatric Population

7.3 Challenges

7.3.1 Stringent Regulatory Compliance

7.3.2 Patent Expiration of Drugs

7.3.3 Side-Effects of Drugs

8. Competitive Landscape

8.1 Drugs Clinical Pipeline

8.2 Financial Analysis

8.3 Market Share Analysis

9. Company Profiles

9.1 AstraZeneca plc

9.2 GlaxoSmithKline plc

9.3 F. Hoffmann-La Roche AG

9.4 Novartis AG

9.5 Merck & Co. Inc.

For more information about this report visit https://www.researchandmarkets.com/r/dzzlx

View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005631/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Inhalers and Nebulisers,Asthma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/09/2019 10:40 AM/DISC: 05/09/2019 10:40 AM

http://www.businesswire.com/news/home/20190509005631/en